Log In
Saturday 24th August 2019

NICE set to reverse decision on prostate cancer drug

16th May 2012

The National Institute for Health and Clinical Excellence (NICE) is set to approve a drug which can treat prostate cancer for use by the health service in England and Wales.


NICE had previously rejected the drug abiraterone in February as being too costly but this provoked criticism from patients and charities.

The drug costs around £3,000 a month per patient and can prolong patients' life expectancy by more than three months.

Janssen, the drug's manufacturer, have offered to provide the tablet at a reduced price and NICE said they would make a final decision in June.

The watchdog's chief executive Sir Andrew Dillon said he was "very pleased" with the outcome.

He commented: "During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.

"This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price; further information on which patients would benefit most and clarification on how many patients could receive the drug."

Owen Sharp, the head of the The Prostate Cancer Charity, said: "This announcement represents a resounding triumph for each of the thousands of men with advanced prostate cancer in England and Wales."

Prostate cancer causes the deaths of around 10,000 men every year in the UK.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2019